Do obsessive-compulsive patients and abstinent heroin addicts share a common psychophysiological mechanism?

Neuropsychobiology

Volumn 47, Issue 1, 2003, Pages 1-11

  Papageorgiou, Charalabos ^a   Rabavilas, Andreas ^a,b   Liappas, Ioannis ^a   Stefanis, Costas ^b  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY MENTAL HEALTH RESEARCH INSTITUTE   (Greece)

Author keywords

Addiction; Attention; Event related potentials; Obsessive compulsive disorder; Opiates; Working memory

Indexed keywords

ADULT; AGE; ANTICIPATION; ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG WITHDRAWAL; EVENT RELATED POTENTIAL; FEMALE; FRONTAL CORTEX; GENDER; HEROIN DEPENDENCE; HUMAN; LATENT PERIOD; MALE; OBSESSIVE COMPULSIVE DISORDER; OCCIPITAL CORTEX; PREFRONTAL CORTEX; PRIORITY JOURNAL; PSYCHOPHYSIOLOGY; SOCIOECONOMICS; WITHDRAWAL SYNDROME; WORKING MEMORY;

ADULT; ATTENTION; EVENT-RELATED POTENTIALS, P300; FEMALE; HEROIN; HUMANS; MALE; MEMORY; OBSESSIVE-COMPULSIVE DISORDER; REACTION TIME; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 0037269603     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000068868     Document Type: Article

References (89)

1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, American Psychiatric Association, 1994.
2. Pitman RK: A cybernetic model of obsessive-compulsive psychopathology. Compr Psychiatry 1987;28:334-343.
3. McDougle JP, Barr CL, Goodman KW, Price HL: Possible role of neuropeptides in obsessive-compulsive disorder. Psychoendocrinology 1999;24:1-24.
4. Carlsson ML: On the role of prefrontal cortex glutamate for the antithetical phenomenology of obsessive-compulsive disorder and attention deficit hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry 2001;25:5-26.
5. Nestler JE, Aghajanian KG: Molecular and cellular basis of addiction. Science 1997;278:58-63.
6. Self DW, Nestler EJ: Relapse to drug-seeking: Neural and molecular mechanisms. Drug Alcohol Depend 1998;51:49-60.
7. Roy BF, Benkelfat C, Hill JL, Pierce PF, Dauphin MM, Kelly TM, Sunderland T, Weinberger DR, Breslin N: Serum antibody for somatostatin-14 and prodynorphin 209-240 in patients with obsessive-compulsive disorder, schizophrenia, Alzheimer's disease, multiple sclerosis, and advanced HIV infection. Biol Psychiatry 1994;35:335-344.
8. Swedo SE, Leonard HL, Kruesi MJ, Rettew DC, Listwak SJ, Berrettini W, Stipetic M, Hamburger S, Gold PW, Potter WZ, et al: Cerebrospinal fluid neurochemistry in children and adolescents with obsessive-compulsive disorder. Arch Gen Psychiatry 1992;49:29-36.
9. Insel TR, Pickar D: Naloxone administration in obsessive-compulsive disorder: Report of two cases. Am J Psychiatry 1983;140:1219-1220.
10. Keuler DJ, Altemus M, Michelson D, Greenberg B, Murphy DL: Behavioral effects of naloxone infusion in obsessive-compulsive disorder. Biol Psychiatry 1996;40:154-156.
11. Hollander E, Bienstock CA, Koran LM, Pallanti S, Marazziti D, Rasmussen SA, Rivizza L, Benkelfat C, Saxena S, Greenberg BD, Sasson Y, Zohar J: Refractory obsessive-compulsive disorder: State-of-the-art treatment. J Clin Psychiatry 2002;63(suppl 6):20-29.
12. Erjavec MK, Coda BA, Nguyen Q, Donaldson G, Risler L, Shen DD: Morphine-fluoxetine interactions in healthy volunteers: Analgesia and side effects. J Clin Pharmacol 2000;40:1286-1295.
13. Luger TJ, Lorenz IH, Grabner-Weiss C, Schlager A, Kolbitsch C, Keller C, Gassner M: Effect of fluvoxamine on sufentanil antinociception and tolerance under chronic intravenous infusion in rats. Pharmacol Toxicol 1999; 85:263-268.
14. Friedman I, Dar R, Shilony E: Compulsivity and obsessionality in opioid addiction. J Nerv Ment Dis 2000;188:155-162.
15. Christensen KJ, Kim SW, Dysken MW, Hoover KM: Neuropsychological performance in obsessive-compulsive disorder. Biol Psychiatry 1992;31:4-18.
16. Purcell R, Maruff P, Kyrios M, Pantelis C: Cognitive deficits in obsessive-compulsive disorder on tests on frontal-striatal function. Biol Psychiatry 1998;43:348-357.
17. Barnett R, Maruff P, Purcell R, Wainwright K, Kyrios M, Brewer W, Pantelis C: Impairment of olfactory identification in obsessive-compulsive disorder. Psychol Med 1999;29:1227-1233.
18. Ornstein TJ, Iddon JL, Baldacchino AM, Sahakian BJ, London M, Everitt BJ, Robbins TW: Profiles of cognitive dysfunction in chronic amphetamine and heroin abusers. Neuropsychopharmacology 2000;23:113-126.
19. Sjogren P, Thomsen AB, Olsen AK: Impaired neuropsychological performance in chronic nonmalignant pain patients receiving long-term oral opioid therapy. J Pain Symptom Manage 2000;19:100-108.
20. Okasha A, Rafaat M, Mahallawy N, El Nahas G, El Dawla AS, Sayed M, El Kholi S: Cognitive dysfunction in obsessive-compulsive disorder. Acta Psychiatr Scand 2000;101:281-285.
21. Leocani L, Locatelli M, Bellodi L, Fornara C, Henin M, Magnani G, Mennea S, Comi G: Abnormal pattern of cortical activation associated with voluntary movement in obsessive-compulsive disorder: An EEG study. Am J Psychiatry 2001;158:140-142.
22. Weinstein AM, Feldtkeller BT, Law F, Myles J, Nutt DJ: The processing of automatic thoughts of drug use and craving in opiate-dependent individuals. Exp Clin Psychopharmacol 2000;8:549-553.
23. Franken IH, Kroon LY, Wiers RW, Jansen A: Selective cognitive processing of drug cues in heroin dependence. J Psychopharmacol 2000;14:395-400.
24. Weiss F, Ciccocioppo R, Parsons LH, Katner S, Liu X, Zorrilla EP, Valdez GR, Ben-Shahar O, Angeletti S, Richter RR: Compulsive drug-seeking behavior and relapse. Neuroadaptation, stress, and conditioning factors. Ann NY Acad Sci 2001;937:1-26.
25. Boutros N, Nasrallah H, Leighty R, Torello M, Tueting P, Olson S: Auditory evoked potentials, clinical vs. research applications. Psychiatry Res 1997;69:183-195.
26. Fabiani M, Gratton G, Coles M: Event-related potentials: Methods, theory, and applications; in Cacioppo J, Tassinary L, Bernston G (eds): Handbook of Psychophysiology. New York, Cambridge University Press, 2000, pp 53-84.
27. Donchin E: Surprise! ... surprise? Psychophysi-ology 1981;18:493-513.
28. Donchin E, Coles MGH: Is the P300 component a manifestation of cognitive updating? Behav Brain Sci 1988;11:357-427.
29. Polich J: P300 clinical utility and control of variability. J Clin Neurophysiol 1998;15:14-33.
30. McEvoy LK, Pellouchoud E, Smith ME, Gevins A: Neurophysiological signals of working memory in normal aging. Brain Res Cogn Brain Res 2001;3:363-376.
31. Lorenz J, Beek H, Bromm B: Cognitive performance, mood and experimental pain before and during morphine-induced analgesia in patients with chronic non-malignant pain. Pain 1997;73:369-375.
32. Kouri EM, Lukas SE, Mendelson JH: P300 assessment of opiate and cocaine users: Effects of detoxification and buprenorphine treatment. Biol Psychiatry 1996;40:617-628.
33. Oades RD, Zerbin D, Dittmann-Balcar A, Eggers C: Auditory event-related potential (ERP) and difference-wave topography in schizophrenic patients with/without active hallucinations and delusions: A comparison with young obsessive-compulsive disorder (OCD) and healthy subjects. Int J Psychophysiol 1996;22:185-214.
34. Sanz M, Molina V, Martin-Loeches M, Calcedo A, Rubia FJ: Auditory P300 event-related potential and serotonin reuptake inhibitor treatment in obsessive-compulsive disorder patients. Psychiatry Res 2001;101:75-81.
35. Towey J, Bruder G, Tenke C, Leite P, DeCaria C, Friedman D, Hollander E: Event-related potential and clinical correlates of neurodysfunction in obsessive-compulsive disorder. Psychiatry Res 1993;49:167-181.
36. Miyata A, Matsunaga H, Kiriike N, Iwasaki Y, Takei Y, Yamagami S: Event-related potentials in patients with obsessive-compulsive disorder. Psychiatry Clin Neurosci 1998;52:513-518.
37. Morault P, Guillem F, Bourgeois M, Paty J: Improvement predictors in obsessive-compulsive disorder. An event-related potential study. Psychiatry Res 1998;81:87-96.
38. Oldfield RC: The assessment and analysis of handedness: The Edinburgh Inventory. Neuropsychologia 1971;9:97-113.
39. Wechsler D: Intelligence (WIS) WAIS Manual. New York, Psychological Corporative, 1955.
40. Papageorgiou C, Liappas I, Asvestas P, Vasios C, Matsopoulos GK, Nikolaou C, Nikita KS, Uzunoglu N, Rabavilas A: Abnormal P600 in heroin addicts with prolonged abstinence elicited during a working memory test. Neuroreport 2001;12:1773-1778.
41. Papageorgiou C, Ventouras E, Uzunoglu N, Rabavilas A, Stefanis C: Changes of P300 elicited during a working memory test in individuals with depersonalization-derealization experiences. Neuropsychobiology, in press.
42. Conklin DM, Courtis C, Katsanis J, Iacono W: Verbal working impairment in schizophrenia patients and their first-degree relatives: Evidence from the digit span task. Am J Psychiatry 2000;157:275-277.
43. Perry W, Heaton RK, Potterat E, Roebuck T, Minassian A, Braff DL: Working memory in schizophrenia: Transient 'online' storage versus executive functioning. Schizophr Bull 2001;27:157-176.
44. Jasper H: The ten-twenty electrode system of the international federation. Electroencephalogr Clin Neurophysiol 1958;10:371-375.
45. Binder J: Functional magnetic resonance imaging: Language mapping. Neurosurg Clin N Am 1997;8:383-392.
46. Holdstock JS, Rugg MD: The effect of attention on the P300 deflection elicited by novel sounds. J Psychophysiol 1995;9:18-31.
47. 3. Brain Res 1989;502:109-116.
48. 3 sources using magnetoencephalography and magnetic resonance imaging. Electroencephalogr Clin Neurophysiol 1991;79:308-321.
49. Ford JM, Sullivan EV, Marsh L, White PM, Lim KO, Pfefferbaum A: The relationship between P300 amplitude and regional gray matter volumes depends upon the attentional system engaged. Electroencephalogr Clin Neurophysiol 1994;90:214-228.
50. Higashima M, Kawasaki Y, Urata K, Maeda Y, Sakai N, Mizukoshi C, Nagasawa T, Kamiya T, Yamaguchi N, Koshino Y, Matsuda H, Tsuji S, Sumiya H, Hisasda K: Simultaneous observation of regional cerebral blood flow and event related potential during performance of an auditory task. Brain Res Cogn Brain Res 1996;4:289-296.
51. Halgren E, Marinkovic K, Chauvel P: Generators of the late cognitive potentials in auditory and visual oddball tasks. Electroencephalogr Clin Neurophysiol 1998;106:156-164.
52. Winterer G, Egan MF, Radler T, Coppola R, Weinberger DR: Event-related potentials and genetic risk for schizophrenia. Biol Psychiatry 2001;50:407-417.
53. McCarley RW, Shenton ME, O'Donnell BF, Faux SF, Kikinis R, Nestor PG, Jolesz FA: Auditory P300 abnormalities and left posterior superior temporal Gyrus volume reduction in schizophrenia. Arch Gen Psychiatry 1993;50:190-197.
54. 2 component in schizophrenia: Relationship to MRI temporal lobe gray matter and to other ERP abnormalities. Biol Psychiatry 1993;34:26-40.
55. Martin-Loeches M, Molina V, Munoz F, Hinojosa JA, Reig S, Desco M, Benito C, Sanz J, Gabiri A, Sarramea F, Santos A, Palomo T: P300 amplitude as a possible correlate of frontal degeneration in schizophrenia. Schizophr Res 2001;49:121-128.
56. Galderisi S, Mucci A, Catapano F, D'Amato AC, Maj M: Neurophysical slowness in obsessive-compulsive patients. Is it confined to test involving the frontal-subcortical systems? Br J Psychiatry 1995;167:394-398.
57. Cox SC: Neuropsychological abnormalities in obsessive-compulsive disorder and their assessments. Int Rev Psychiatry 1997;9:45-59.
58. Bussato FG, Zamignani RD, Buchpiguel AC, Garrido EG, Glabus FM, Rocha TE, Maia FA, Rosario-Campos CM, Campi Castro C, Furuie SS, Gutierrez AM, McGuire KP, Miguel CE: A voxel-based investigation in obsessive-compulsive disorder using single emission computer tomography (SPECT). Psychiatry Res 2000;99:15-27.
59. Greenberg BD, George MS, Martin JD, Benjamin J, Schlaepfer TE, Altemus M, Wassermann EM, Post RM, Murphy DL: Effect of prefrontal repetitive transcranial magnetic stimulation in obsessive-compulsive disorder: A preliminary study. Am J Psychiatry 1997;154:867-869.
60. Jones AK, Friton KJ, Qi LY, Harris M, Cunninghan VJ, Jones T, Feinman C, Frackowiak RS: Sites of action of morphine in the brain. Lancet 1991;338:825.
61. Robinson TE, Berridge KC: The neural basis of drug craving: An incentive-sensitization theory of addiction. Brain Res Brain Res Rev 1993;18:247-291.
62. Paik SH, Camarao GC, Bauer JA, Leite PE, Oliveira ES, Camargo AC, Farges RC: Effects of morphine withdrawal syndrome on endooligopeptidase (EC 3.4.22.19) activity. Eur J Pharmacol 1994;253:101-106.
63. Danos P, Krappel C, Broich K, Hoflich G, Overbeek B, Biersack HJ, Moller HJ: Pathological regional blood flow in opiate-dependent patients during withdrawal: A HMPAO-SPECT study. Neuropsychobiology 1998;37:194-199.
64. Schlaepfer TE, Strain EC, Greenberg BD, Preston KL, Lancaster E, Bigelow GE, Barta PE, Pearlson GD: Site of opioid action in the human brain: Mu and kappa agonists' subjective and cerebral blood flow effects. Am J Psychiatry 1998;155:470-473.
65. Modell JG, Mountz JM, Beresford TP: Basal ganglia/limbic striatal and thalamocortical involvement in craving and loss of control in alcoholism. J Neuropsychiatry Clin Neurosci 1990;2:123-144.
66. Curran HV, Kleckham J, Bearn J, Strang J, Wanigaratne S: Effects of methadone on cognition, mood and craving in detoxifying opiate addicts: A dose-response study. Psychopharmacology (Berl) 2001;154:153-160.
67. Ohno M, Watanabe S: Intrahippocampal administration of (+)-SKF 10,047, a sigma ligand, reverses MK-801-induced impairment of working memory in rats. Brain Res 1995;684:237-242.
68. Giacchino JL, Henriksen SJ: Opioid effects on activation of neurons in the medical prefrontal cortex. Prog Neuropsychopharmacol Biol Psychiatry 1998;22:1157-1178.
69. Li Z, Wu CF, Pei G, Xu NJ: Reversal of morphine-induced memory impairment in mice by withdrawal in Morris water maze: Possible involvement of cholinergic system. Pharmacol Biochem Behav 2001;68:507-513.
70. Lubman DI, Peters LA, Mogg K, Bradley BP, Deakin JF: Attentional bias for drug cues in opiate dependence. Psychol Med 2000;30:169-175.
71. Koob GF, Le Moal M: Drug abuse: Hedonic homeostatic dysregulation. Science 1997;278:52-58.
72. Selby MJ, Azrin RL: Neuropsychological functioning in drug abusers. Drug Alcohol Depend 1998;50:39-45.
73. Malloy P, Rasmussen S, Braden W, Haier RJ: Topographic evoked potential mapping in obsessive-compulsive disorder: Evidence of frontal lobe dysfunction. Psychiatry Res 1989;28:63-71.
74. Enoch MA, White KV, Harris CR, Rohrbaugh JW, Goldman D: Alcohol use disorders and anxiety disorders: Relation to the P300 event-related potential. Alcohol Clin Exp Res 2001;25:1293-1300.
75. Mathalon DH, Ford JM, Pfefferbaum A: Trait and state aspects of P300 amplitude reduction in schizophrenia: A retrospective longitudinal study. Biol Psychiatry 2000;47:434-449.
76. Daffner KR, Rentz DM, Scinto LF, Faust R, Budson AE, Holcomb PJ: Pathophysiology underlying diminished attention to novel events in patients with early AD. Neurology 2001;56:1377-1383.
77. Tracy J: Nonspecific abnormalities in psychiatry: Do they reflect an ordered pathway of brain dysfunction? Biol Psychiatry 1995;38:207-209.
78. O'Donnell BF, Faux SF, McCarley RW, Kimble MO, Salisbury DF, Nestor PG, Kikinis R, Jolesz FA, Shenton ME: Increased rate of P300 latency prolongation with age in schizophrenia. Electrophysiological evidence for a neurodegenerative process. Arch Gen Psychiatry 1995;5:544-549.
79. Bauer LO: Effect of chronic opioid dependence and HIV-1 infection on pattern shift visual evoked potentials. Drug Alcohol Depend 1998;50:147-155.
80. Frodl-Bauch T, Bottlender R, Hegerl U: Neurochemical substrates and neuroanatomical generators of the event-related P300. Neuropsychobiology 1999;40:86-94.
81. Joel D, Avisar A: Excessive lever pressing following post-training signal attenuation in rats: A possible animal model of obsessive-compulsive disorder? Behav Brain Res 2001;123:77-87.
82. Petty F, Davis LL, Kabel D, Kramer GL: Serotonin dysfunction disorders: A behavioral neurochemistry perspective. J Clin Psychiatry 1996;57(suppl 8):11-16.
83. Carlsson ML: On the role of prefrontal cortex glutamate for the antithetical phenomenology of obsessive-compulsive disorder and attention deficit hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry 2001;25:5-26.
84. Sell LA, Morris J, Bearn J, Frackowiak RS, Friston KJ, Dolan RJ: Activation of reward circuitry in human opiate addicts. Eur J Neurosci 1999;11:1042-1048.
85. Schoeffelmeer AN, Wardeh G, Vanderschuren LJ: Morphine acutely and persistently attenuates nonvesicular GABA release in rat nucleus accumbens. Synapse 2001;42:87-94.
86. Kobayashi H, Suzuki T, Kamata R, Saito S, Sato I, Tsuda S, Matsusaka N: Recent progress in the neurotoxicology of natural drugs associated with dependence or addiction, their endogenous agonists and receptors. J Toxicol Sci 1999;24:1-16.
87. Klein T, Anderson RL: The behavioral high-risk paradigm in the mood disorders; in Miller GA (ed): The Behavioral High-Risk Paradigm in Psychopathology. New York, Springer, 1995, pp 199-221.
88. 1 and P300 abnormalities in patients with schizophrenia, epilepsy, and epilepsy with schizophrenia-like features. Biol Psychiatry 2001;49:848-860.
89. Leshner AI: The disease of addiction. Lippin-cotts Prim Care Pract 2000;4:249-253.